KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Other Non-Current Liabilities: 2009-2024

Historic Other Non-Current Liabilities for Acadia Pharmaceuticals (ACAD) over the last 9 years, with Dec 2024 value amounting to $18.1 million.

  • Acadia Pharmaceuticals' Other Non-Current Liabilities fell 9.35% to $13.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 million, marking a year-over-year decrease of 9.35%. This contributed to the annual value of $18.1 million for FY2024, which is 19.21% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Other Non-Current Liabilities stood at $18.1 million for FY2024, which was up 19.21% from $15.1 million recorded in FY2023.
  • In the past 5 years, Acadia Pharmaceuticals' Other Non-Current Liabilities registered a high of $18.1 million during FY2024, and its lowest value of $5.2 million during FY2020.
  • In the last 3 years, Acadia Pharmaceuticals' Other Non-Current Liabilities had a median value of $15.1 million in 2023 and averaged $14.1 million.
  • Data for Acadia Pharmaceuticals' Other Non-Current Liabilities shows a peak YoY surged of 81.06% (in 2020) over the last 5 years.
  • Over the past 5 years, Acadia Pharmaceuticals' Other Non-Current Liabilities (Yearly) stood at $5.2 million in 2020, then skyrocketed by 35.79% to $7.0 million in 2021, then climbed by 29.00% to $9.1 million in 2022, then spiked by 66.93% to $15.1 million in 2023, then climbed by 19.21% to $18.1 million in 2024.